Trials / Recruiting
RecruitingNCT06453057
Autologous Tumor-Infiltrating Lymphocyte (GT307) for Treatment of Patients With Solid Tumours
A Single-arm Clinical Study of Autologous Tumor-Infiltrating Lymphocyte (GT307) for Treatment of Patients With Solid Tumours
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 18 (estimated)
- Sponsor
- Grit Biotechnology · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This study is a single arm, open design aimed at evaluating the safety and tolerability of Autologous Tumor-Infiltrating Lymphocyte (GT307) for treatment of patients with solid tumours,while evaluating pharmacokinetic characteristics and efficacy assessment to determine the optimal biological dose (OBD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | GT307 injection | GT307 injection to treat solid tumours |
Timeline
- Start date
- 2024-07-04
- Primary completion
- 2027-06-06
- Completion
- 2027-06-06
- First posted
- 2024-06-11
- Last updated
- 2026-04-14
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06453057. Inclusion in this directory is not an endorsement.